197 Medical isotope production at TRIUMF and future collaboration with MEDICIS-PROMED  by Seimbille, Y.
S96  ICTR-PHE 2016 
 
[2] Friedrich, T. et al. Int. J. Radiat. Biol. 88,    103-107 
(2012) 
[3] Friedrich, T. et al., Radiat. Res. 178, 385-394 (2012) 
[4] Herr L. et al, PLoS One, 9, e83923 (2014) 
[5] Tommasino, F. et al., Radiat. Res. 180, 524-538 (2013) 
[6] Friedrich T. et al., Radiat. Res., 181, 485-94 (2014) 
[7] Hufnagl A. et al., DNA Repair 27 :28-39 (2015)XXX 
 
196 
Helium and Oxygen beam models in TRiP98: 
implementation, treatment planning tests and 
experimental verification 
E. Scifoni1, O. Sokol1, R. Grün1, T. Friedrich1, M. Scholz1, W. 
Tinganelli1, S. Brons2, C. Schuy1, M. Rovituso1, M. Durante1 
and M. Krämer1  
1 Biophysics Dept., GSI Helmholtzzentrum für 
Schwerionenforschung, Darmstadt (D)  
2 Heidelberger Ionenstrahl-Therapiezentrum (HIT), Heidelberg 
(D)   
 
Since some of the most modern ion therapy facilities are 
offering or considering the irradiation with alternative ion 
beams, beyond proton and carbon, it has raised new 
attention the need for a proper description of these beams, 
in order to exploit their use for specific applications. In 
particular, helium and oxygen beams are presently available 
in the research cave of the Heidelberg Ion therapy facility 
(HIT). 
We developed and integrated in TRiP98, our research 
treatment planning system, specific beam models for these 
ions, which have been validated experimentally on different 
levels. 
For the Helium beam a semiempirical model for dose 
deposition and fragmentation was implemented, by 
modification of algorithms conventionally used in space 
radiation transport studies, translated to the typical 
therapeutic range of energies [1]. 
For Oxygen beam, the standard transport model of TRiP98 
was tuned on recent attenuation experiments and the 
fragmentation cascade has been improved using the latest 
beam models of the low-lying ions. 
Several treatment planning tests have been performed, 
showing no universal indications but rather selective 
advantages of the different beams, and revealing for 
example a considerable convenience of using Helium beams 
in specific configurations [2], or proposing combination of 
different ions [3]. 
Experimental verification has been performed for both ion 
beams at the experimental room of HIT, analyzing different 
endpoints: basics physics data, delivered 3D physical dose 
distribution and biological effect. Monoenergetic and 
extended target irradiations of different extensions with 
single and double opposed fields have been verified. In the 
case of oxygen beams, considering that its main importance 
is related to a possible indication for partially hypoxic 
tumors, the biological verification was extended beyond the 
RBE weighted dose effect, but also including the OER effect.  
As previously obtained with carbon ions [4], the kill-painting 
method, allowing to restore an homogeneous survival level 
on a differently oxygenated target, was verified with oxygen 
beams. It is found that with the latter ion beams, for a 
partially hypoxic target an inversion of the relative profile 
occurs, as compared to a normoxic case, with a slightly 
reduced normal tissue damage for same  cell killing in the 
target than with  the carbon irradiation. 
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The demand for personalized medicine is increasing, and 
considering that the population suffering from chronic 
diseases (i.e. cancer, Alzeihmer) is continuously growing it is 
expected that the consumption of molecular diagnostic 
products and radiotherapeutics will continue to increase. In 
this scenario, TRIUMF and its fleet of proton accelerators 
ranging from 13 to 500 MeV is offering a unique environment 
for scientists to enable the production of isotopes with 
potential applications in molecular imaging or radiotherapy. 
A multidisciplinary program involving target design, isotope 
production and radiopharmaceutical chemistry has emerged 
in the Division of Life Sciences to facilitate and accelerate 
the translation from bench-to-bedside. 
A brief overview of the recent efforts related to the 
production and applications of medical isotopes at TRIUMF 
will be presented. Comprehensive studies have been 
conducted to improve the production of conventional PET 
isotopes by a better understanding of the physical 
phenomenon occurring inside the target during beam 
irradiation. Feasibility of the production, from liquid targets, 
of radiometals (i.e. 44Sc, 68Ga, 86Y and 89Zr) used in medical 
imaging has also been demonstrated. The results of the ITAP 
project, led by TRIUMF and including a consortium of 
institutions, on accelerator-based production of 99mTc will be 
discussed. It has been shown that a reliable commercial scale 
(TBq) production of 99mTc is achievable by using 100Mo coated 
tantalum targets at energies up to 24 MeV. Investigations on 
the production and isolation of the therapeutic isotope 211At 
and its imaging companion 209At will be mentioned.  
Novel radiolabeling strategies and technologies have recently 
emerged to prepare radiopharmaceuticals and will be 
discussed. Isotopic exchange reactions are getting popular to 
rapidly and efficiently synthesize PET imaging probes. Click 
chemistry is also representing an attractive approach to 
radiolabel molecules because of its simple process, short 
reaction times and clean product synthesis. Microfluidic 
devices bear great promises in the field of radiochemistry as 
it is expected that they will allow faster reaction rate, 
exquisite reaction selectivity, reduced reagent consumption, 
and possibly revisit the hot-lab concept. An overview of the 
tracer development performed at TRIUMF (e.g. cysteine 
transporter, angiogenesis) will be presented. 
Finally, within the framework of the MEDICIS-PROMED 
consortium, a collaboration between TRIUMF and the 
Institute of Translational Molecular Imaging (ITMI) at the 
University Hospital of Geneva and the Laboratory of 
Bioorganic Chemistry and Molecular Imaging at EPFL will soon 
take place. This presentation will conclude with a short 
summary of our ambitious project on the development of 
dual modality molecular probes for ovarian cancer and their 
preclinical validations in animal models. 
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Purpose: The main purpose of the present work is to evaluate 
the effects of gold nanoparticles (GNPs) in different sizes and 
concentrations on cancer cells which undergo treatment with 
photon therapy.  
